Trevi Therapeutics Inc.(TRVI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TRVI Trevi Therapeutics Inc.

盘前交易 06-09 07:59:13 EDT

13.50

+0.17

+1.28%

盘前13.41

-0.09-0.67%

07:42 EDT

最高13.64	最低13.33	成交量69.75万
今开13.57	昨收13.33	日振幅2.29%
总市值19.17亿	流通市值15.66亿	总股本1.42亿
成交额942.13万	换手率0.60%	流通股本1.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TRVI","market":"US","secType":"STK","nameCN":"Trevi Therapeutics Inc.","latestPrice":13.5,"timestamp":1780948800000,"preClose":13.33,"halted":0,"volume":697523,"hourTrading":{"tag":"盘前","latestPrice":13.41,"preClose":13.5,"latestTime":"07:42 EDT","volume":117,"amount":1573.7199659999999,"timestamp":1781005352165,"change":-0.09,"changeRate":-0.006667,"amplitude":0.10963},"delay":0,"changeRate":0.012753188297074263,"floatShares":115999999,"shares":142000000,"eps":-0.321787,"marketStatus":"盘前交易","change":0.17,"latestTime":"06-09 07:59:13 EDT","open":13.57,"high":13.635,"low":13.33,"amount":9421292.147270499,"amplitude":0.022881,"askPrice":15.08,"askSize":100,"bidPrice":13.4,"bidSize":172,"shortable":3,"etf":0,"ttmEps":-0.321787,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781011800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1557201600000,"exchange":"NASDAQ","adjPreClose":13.5,"preHourTrading":{"tag":"盘前","latestPrice":13.41,"preClose":13.5,"latestTime":"07:42 EDT","volume":117,"amount":1573.7199659999999,"timestamp":1781005352165,"change":-0.09,"changeRate":-0.006667,"amplitude":0.10963},"postHourTrading":{"tag":"盘后","latestPrice":13.24,"preClose":13.5,"latestTime":"19:15 EDT","volume":18828,"amount":253871.89,"timestamp":1780960533868,"change":-0.26,"changeRate":-0.019259,"amplitude":0.02},"volumeRatio":0.7965728510981018,"impliedVol":0.2716,"impliedVolPercentile":0.156},"requestUrl":"/m/hq/s/TRVI/tweets","defaultTab":"tweets","newsList":[{"id":"1166283059","title":"Trevi Therapeutics宣布在美国胸科学会2026年国际会议上进行口头报告及多篇海报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1166283059","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166283059?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:06","pubTimestamp":1777579591,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics公司近日宣布，其研究成果已获选在美国胸科学会（ATS）2026年国际会议上进行展示。此次入选包括一场重磅的口头学术报告以及多篇壁报展示，彰显了该公司在呼吸疾病治疗领域的科研实力。\n该会议是全球呼吸病学领域的权威学术盛会，汇集了来自世界各地的顶尖专家学者。Trevi Therapeutics此次多项研究成果同时获得展示机会，反映了行业对其创新疗法的高度关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118580746","title":"Trevi Therapeutics将于2026年5月5日公布2026年第一季度财务业绩并更新公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1118580746","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118580746?lang=zh_cn&edition=full","pubTime":"2026-04-29 04:06","pubTimestamp":1777406808,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics宣布，计划于2026年5月5日发布2026年第一季度财务报告。此次公告将详细披露公司该季度的财务表现，同时管理层将同步更新企业最新运营进展。\n投资者可通过官方渠道获取具体财报发布时间及电话会议参与方式。此次披露将涵盖公司研发管线推进、业务战略实施等关键信息，为市场提供全面评估企业价值的依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115266921","title":"Trevi Therapeutics完成1.73亿美元承销发行 承销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1115266921","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115266921?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:08","pubTimestamp":1776715692,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Trevi Therapeutics近日宣布，其此前公布的承销公开发行已正式完成。本次发行以每股13.00美元的价格公开发行13,340,000股普通股，其中包括承销商全额行使期权，以发行价额外购买的1,740,000股普通股。在扣除承销折扣和佣金前，本次发行总收益约为1.73亿美元。所有发行股份均由Trevi公司售出。Trevi拟将Haduvio作为口服纳布啡缓释片的商品名。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0882574139.USD","LU0106831901.USD","LU0314104364.USD","LU1548497426.USD","LU2023251221.USD","BK4539","MS","TM","LU2357305700.SGD","LU1244550221.USD","LU1732799900.SGD","LU0106261372.USD","BK4581","LU2089283258.USD","LU0557290698.USD","BK4099","LU0225283273.USD","RCC","BK4534","LU0234570918.USD","LENZ","LU2028103732.USD","LU1162221912.USD","LU1732800096.USD","IE00BZ1G4Q59.USD","LU0528227936.USD","LU0267386448.USD","LU1720051017.SGD","LU1791710582.SGD","BK4127","LU2111349929.HKD","TRVI","IE00BKVL7J92.USD","BK4007","LU0098860793.USD","LU0006306889.USD","LU1989772840.SGD","BK4516","BK4504","LU0795875169.SGD","LU1244550494.USD","LU1668664300.SGD","LU2089284900.SGD","LU2271345857.HKD","BK4555","LU0158827948.USD","LU1720051108.HKD","LU0795875086.SGD","03160","LU0320765646.SGD","LU1791710400.SGD","LU2347655156.SGD","LU2133065610.SGD","BK4604","LU1074936037.SGD","LU1989772923.USD","LU1363072403.SGD","BK4139","LU1244550577.SGD","LU0971096721.USD","BK4588","LU0912757837.SGD","LU0158827781.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144003495","title":"Trevi Therapeutics盘后重挫5.6% 宣布拟公开发行普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1144003495","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144003495?lang=zh_cn&edition=full","pubTime":"2026-04-17 04:18","pubTimestamp":1776370707,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Inc. (TRVI) 股价在盘后交易时段遭遇抛压，大幅下挫5.6%。此番波动紧随该公司宣布的一项重大融资决策：其计划进行普通股的公开发行。\n市场对此消息反应迅速，表明投资者可能担忧股权稀释效应。此次公开发行的具体条款，包括发行规模及定价，尚未最终确定，将成为市场后续关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138495751","title":"Trevi Therapeutics宣布拟进行普通股公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1138495751","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138495751?lang=zh_cn&edition=full","pubTime":"2026-04-17 04:11","pubTimestamp":1776370286,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Trevi Therapeutics今日宣布，已启动承销式公开发行，计划发售总值1.5亿美元的普通股。本次发行全部股份均由Trevi提供。公司还拟授予承销商30天超额配售选择权，可额外认购最多2250万美元的普通股，发行价格将扣除承销折扣与佣金。摩根士丹利、Leerink Partners、Cantor及Stifel担任此次发行的联席账簿管理人，Oppenheimer & Co.则出任牵头经理。Trevi计划将Haduvio作为口服纳布啡缓释片的商品名，其安全性与有效性尚未获得任何监管机构评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","LU0912757837.SGD","LU1074936037.SGD","BK4604","LU1668664300.SGD","LU2089284900.SGD","BK4127","BK4555","LU1732799900.SGD","TM","LU1732800096.USD","LU1791710582.SGD","MS","LU0106261372.USD","LU2023251221.USD","LU0006306889.USD","LU0795875169.SGD","LU0267386448.USD","LU1244550221.USD","BK4007","BK4588","03160","LU0158827781.USD","LU0225283273.USD","LU1363072403.SGD","LU1720051108.HKD","LU1791710400.SGD","LU1162221912.USD","LU2111349929.HKD","LU2089283258.USD","LU0882574139.USD","LU0320765646.SGD","LU0314104364.USD","LU1548497426.USD","LU2357305700.SGD","BK4534","BK4504","LU0971096721.USD","LU0098860793.USD","TRVI","BK4539","LU1720051017.SGD","LU0234570918.USD","LU2347655156.SGD","BK4516","LU0795875086.SGD","LU1244550494.USD","RCC","BK4581","LU0158827948.USD","BK4139","IE00BKVL7J92.USD","LU0528227936.USD","LU2028103732.USD","LU0106831901.USD","LU1244550577.SGD","LU1989772840.SGD","BK4099","BK4585","LENZ","LU2271345857.HKD","LU2133065610.SGD","LU1989772923.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134787233","title":"Trevi Therapeutics公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1134787233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134787233?lang=zh_cn&edition=full","pubTime":"2026-03-18 04:06","pubTimestamp":1773777974,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics, Inc. (以下简称\"公司\")近日正式披露了其2025年第四季度及全年的财务报告，同时向市场同步了最新的业务发展动态。此次公告涵盖了公司在关键财务指标上的表现，以及研发管线、战略布局等方面的最新进展，为投资者提供了全面的运营概览。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190586360","title":"Trevi Therapeutics将于2026年3月17日公布2025年第四季度及全年财报并举行业务进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1190586360","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190586360?lang=zh_cn&edition=full","pubTime":"2026-03-11 04:07","pubTimestamp":1773173233,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Inc. (TRVI) 宣布，公司计划于2026年3月17日发布2025年第四季度及全年度的财务业绩报告。届时，管理层还将同步更新公司的最新业务动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139169921","title":"Trevi Therapeutics宣布完成与FDA的二期临床试验结束会议，就特发性肺纤维化相关慢性咳嗽研发计划达成共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1139169921","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139169921?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:31","pubTimestamp":1773055909,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics（TRVI）已顺利完成与美国食品药品监督管理局（FDA）的二期临床试验结束会议。双方就该公司针对特发性肺纤维化相关慢性咳嗽的研发计划达成重要共识，为后续临床开发路径奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126825574","title":"Trevi Therapeutics宣布Nalbuphine ER治疗特发性肺纤维化慢性咳嗽的IIb期试验数据发表于《美国医学会杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1126825574","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126825574?lang=zh_cn&edition=full","pubTime":"2026-01-23 01:30","pubTimestamp":1769103015,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics公司近日宣布，其针对特发性肺纤维化（IPF）相关慢性咳嗽的Nalbuphine ER缓释片IIb期临床试验数据，已正式发表于国际权威医学期刊《美国医学会杂志》（JAMA）。\n该试验旨在评估Nalbuphine ER在缓解IPF患者慢性咳嗽症状方面的有效性与安全性。研究结果的公开发表，为这一潜在疗法的临床价值提供了重要的学术支持。\n数据的发布标志着Trevi Therapeutics在呼吸系统疾病治疗领域取得了阶段性进展，也为后续临床开发奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117780818","title":"Trevi Therapeutics在摩根大通医疗健康年会期间举办的企业交流活动前公布战略动向","url":"https://stock-news.laohu8.com/highlight/detail?id=1117780818","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117780818?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:32","pubTimestamp":1767875527,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics公司于近期披露了关键战略更新，此举恰逢在摩根大通医疗健康年会期间举行的年度LifeSci Partners企业交流活动前夕。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","LU2023250843.SGD","LU0820562030.AUD","LU2430703095.HKD","IE000M9KFDE8.USD","IE00BWXC8680.SGD","IE00BJLML261.HKD","LU1974910355.USD","LU1261432733.SGD","LU2357305700.SGD","LU0211326755.USD","IE0034235303.USD","LU0208291251.USD","LU1894683264.USD","LU2552382215.SGD","LU2746668461.USD","LU1670627923.USD","BK4007","LU0048584097.USD","LU2456880835.USD","LU2237443549.SGD","LU0345770308.USD","LU2505996681.GBP","BK4534","LU1366192091.USD","IE0034235295.USD","SG9999002224.SGD","LU0265550946.USD","LU0215105999.USD","LU1914381329.SGD","LU0868494617.USD","LU1244550494.USD","BK4207","BK4566","LU0203345920.USD","IE00B775SV38.USD","LU0820561818.USD","LU2505996509.AUD","IE00BJTD4V19.USD","LU1720051017.SGD","IE00BDRTCR15.USD","BK4585","IE00BZ1G4Q59.USD","LU1629891620.HKD","TRVI","LU0976567544.SGD","LU1064131342.USD","LU2264538146.SGD","LU0417517546.SGD","IE00BKVL7J92.USD","LU0211326839.USD","LU0496365809.HKD","IE00BBT3K403.USD","LU2552382058.USD","LU1496350171.SGD","LU1119994496.HKD","LU0320765489.SGD","LU2237443382.USD","IE00BDCRKT87.USD","LU0942090050.USD","LU1551013342.USD","LU2242649171.HKD","IE00BLSP4239.USD","LU1720051108.HKD","LU0211331839.USD","LU0149725797.USD","LU2213496289.HKD","LU2381873111.SGD","LU1917777945.USD","LU0106261372.USD","LU2023250504.SGD","LU2756315664.SGD","LU0868494708.USD","LU0265550359.USD","BK4516","LU0345769631.USD","LU2054465674.USD","LU2237443465.HKD","IE00BYXW3230.USD","LU1244550577.SGD","LU2236285917.USD","BK4581","LU1280957306.USD","BK4588","LU1116320901.HKD","LU0964807845.USD","LU0070302665.USD","LU0256863811.USD","LU2462157665.USD","LU2211815571.USD","LU0211328371.USD","LU1116320737.USD","LU0820561909.HKD","LU0971096721.USD","LU0640476718.USD","LU1548497426.USD","IE00B1BXHZ80.USD","LU2756315318.SGD","LU2106854487.HKD","LU0170899867.USD","LU1363072403.SGD","LU2552382132.HKD","LU0203347892.USD","LU0683600562.USD","LU1988902786.USD","LU0882574139.USD","LU1244550221.USD","BK4550","LU1894683348.USD","LU2023250330.USD","LU0787776722.HKD","BK4504","LU2237443978.SGD","LU2746668974.SGD","LU0323591593.USD","LU2430703178.SGD","LU2237443622.USD","LU1032466523.USD","LU1496350502.SGD","LU0251132253.USD","IE00BFXG1179.USD","LU0320765646.SGD","LU1668664300.SGD","IE00BN8TJ469.HKD","LU0006306889.USD","IE00BKDWB100.SGD","IE0034235188.USD","LU0345769128.USD","BK4533","IE00BLSP4452.SGD","LU1670628061.USD","LU0310799852.SGD","LU1162221912.USD","LU1267930490.SGD","LU1084165304.USD","SG9999002232.USD","IE00BJTD4N35.SGD","LU0943347566.SGD","LU1551013425.SGD","IE00BHPRN162.USD","LU2237443895.HKD","LU0689472784.USD","LU2430703251.USD","LU1145028129.USD","LU0267386448.USD","LU0211327993.USD","LU0234572021.USD","IE00B1XK9C88.USD","LU0238689110.USD","LU0106831901.USD","LU2592432038.USD","IE00B3S45H60.SGD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518205376","title":"HC Wainwright & Co.：维持Trevi Therapeutics(TRVI.US)评级，由买入调整至买入评级, 目标价由7.50美元调整至12.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518205376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518205376?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:41","pubTimestamp":1741628499,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Trevi Therapeutics(TRVI.US)评级，由买入调整至买入评级, 目标价由7.50美元调整至12.50美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11014148641576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TRVI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518275991","title":"Trevi Therapeutics, Inc.盘中异动 早盘急速上涨53.49%报6.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275991","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518275991?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:30","pubTimestamp":1741613405,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时30分，Trevi Therapeutics, Inc.股票出现异动，股价大幅拉升53.49%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213005a26a23d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213005a26a23d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516666876","title":"Trevi Therapeutics, Inc.盘中异动 急速下挫5.09%报4.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516666876?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:14","pubTimestamp":1741032851,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时14分，Trevi Therapeutics, Inc.股票出现波动，股价快速跳水5.09%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041412abe69252&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041412abe69252&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378194","title":"Trevi Therapeutics, Inc.盘中异动 股价大跌7.33%报4.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514378194?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753062,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Trevi Therapeutics, Inc.股票出现异动，股价急速下挫7.33%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502282231029896796a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502282231029896796a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514389009","title":"Trevi Therapeutics, Inc.盘中异动 股价大涨5.10%报4.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514389009?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:20","pubTimestamp":1740669609,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时20分，Trevi Therapeutics, Inc.股票出现异动，股价急速上涨5.10%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.94%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232009abdf7bad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232009abdf7bad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","TRVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514041811","title":"Trevi Therapeutics, Inc.盘中异动 快速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514041811","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514041811?lang=zh_cn&edition=full","pubTime":"2025-02-26 04:58","pubTimestamp":1740517139,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日04时58分，Trevi Therapeutics, Inc.股票出现波动，股价急速上涨5.10%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045859abdcd5f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045859abdcd5f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TRVI","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514702770","title":"Trevi Therapeutics, Inc.盘中异动 下午盘大幅下挫5.54%报4.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514702770","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514702770?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:29","pubTimestamp":1740425356,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时29分，Trevi Therapeutics, Inc.股票出现异动，股价快速跳水5.54%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.37%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225032917962ed3f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225032917962ed3f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513729972","title":"Trevi Therapeutics, Inc.盘中异动 股价大涨5.21%报5.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513729972?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:30","pubTimestamp":1740148229,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时30分，Trevi Therapeutics, Inc.股票出现异动，股价快速上涨5.21%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223030988dddc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223030988dddc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512435232","title":"Trevi Therapeutics, Inc.盘中异动 快速上涨5.09%报4.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512435232","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512435232?lang=zh_cn&edition=full","pubTime":"2025-02-20 03:19","pubTimestamp":1739992789,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日03时19分，Trevi Therapeutics, Inc.股票出现波动，股价快速上涨5.09%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.58%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220031949abd53208&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220031949abd53208&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","TRVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512193256","title":"Trevi Therapeutics, Inc.盘中异动 急速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512193256?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:06","pubTimestamp":1739902005,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时06分，Trevi Therapeutics, Inc.股票出现波动，股价快速拉升5.04%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219020646988a201e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219020646988a201e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TRVI","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trevitherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.069},{"period":"3month","weight":0.148},{"period":"6month","weight":-0.0473},{"period":"1year","weight":0.9122},{"period":"ytd","weight":0.0783}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Trevi Therapeutics, Inc.于2011年3月17日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于开发和商业化Haduvio，一种口服缓释纳布啡制剂，用于治疗与特发性肺纤维化、其他间质性肺病和难治性慢性咳嗽相关的慢性咳嗽。它保留了该在研疗法的全球商业权利。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.062028},{"month":2,"riseRate":0.857143,"avgChangeRate":0.194268},{"month":3,"riseRate":0.571429,"avgChangeRate":0.340057},{"month":4,"riseRate":0.571429,"avgChangeRate":0.129333},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.1063},{"month":6,"riseRate":0.625,"avgChangeRate":0.178838},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.013323},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.078417},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065787},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.063981},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.046063},{"month":12,"riseRate":0.571429,"avgChangeRate":0.034671}],"exchange":"NASDAQ","name":"Trevi Therapeutics Inc.","nameEN":"Trevi Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Trevi Therapeutics Inc.(TRVI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Trevi Therapeutics Inc.(TRVI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Trevi Therapeutics Inc.,TRVI,Trevi Therapeutics Inc.股票,Trevi Therapeutics Inc.股票老虎,Trevi Therapeutics Inc.股票老虎国际,Trevi Therapeutics Inc.行情,Trevi Therapeutics Inc.股票行情,Trevi Therapeutics Inc.股价,Trevi Therapeutics Inc.股市,Trevi Therapeutics Inc.股票价格,Trevi Therapeutics Inc.股票交易,Trevi Therapeutics Inc.股票购买,Trevi Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Trevi Therapeutics Inc.(TRVI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Trevi Therapeutics Inc.(TRVI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}